Donghua Yin

2.7k total citations
45 papers, 2.1k citations indexed

About

Donghua Yin is a scholar working on Endocrinology, Diabetes and Metabolism, Oncology and Immunology. According to data from OpenAlex, Donghua Yin has authored 45 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Endocrinology, Diabetes and Metabolism, 15 papers in Oncology and 14 papers in Immunology. Recurrent topics in Donghua Yin's work include Biosimilars and Bioanalytical Methods (14 papers), Hormonal and reproductive studies (8 papers) and HER2/EGFR in Cancer Research (8 papers). Donghua Yin is often cited by papers focused on Biosimilars and Bioanalytical Methods (14 papers), Hormonal and reproductive studies (8 papers) and HER2/EGFR in Cancer Research (8 papers). Donghua Yin collaborates with scholars based in United States, United Kingdom and Canada. Donghua Yin's co-authors include Antonio Gualberto, James T. Dalton, Duane D. Miller, Paul Haluska, Johann S. de Bono, Yali He, M. Luisa Paccagnella, Amarnath Sharma, L Rhoda Molife and Craig Marhefka and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Gastroenterology.

In The Last Decade

Donghua Yin

42 papers receiving 2.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Donghua Yin United States	24	813	804	584	582	361	45	2.1k
Harold Keer United States	21	1.3k 1.6×	371 0.5×	627 1.1×	1.2k 2.1×	610 1.7×	75	2.6k
Jean Charles Soria France	25	1.5k 1.8×	469 0.6×	1.2k 2.1×	965 1.7×	561 1.6×	48	3.1k
Jan Willem B. de Groot Netherlands	27	1.5k 1.9×	829 1.0×	1.9k 3.2×	367 0.6×	241 0.7×	94	3.2k
Frauke Bentzien United States	10	821 1.0×	248 0.3×	665 1.1×	522 0.9×	298 0.8×	12	2.1k
Suneel Mundle United States	28	913 1.1×	307 0.4×	560 1.0×	1.5k 2.6×	638 1.8×	131	3.3k
L. Rhoda Molife United Kingdom	25	1.3k 1.6×	326 0.4×	1.3k 2.2×	1.5k 2.6×	680 1.9×	73	3.0k
James R. Vasselli United States	21	1.6k 2.0×	1.2k 1.5×	1.2k 2.1×	1.2k 2.0×	1.1k 3.1×	37	3.7k
Hiroshi Sonoo Japan	26	820 1.0×	335 0.4×	1.3k 2.3×	292 0.5×	645 1.8×	123	2.3k
Michael T. Schweizer United States	33	929 1.1×	346 0.4×	1.1k 1.9×	2.2k 3.7×	746 2.1×	144	3.1k
Ryan J. Hartmaier United States	24	878 1.1×	319 0.4×	936 1.6×	948 1.6×	687 1.9×	63	2.1k

Countries citing papers authored by Donghua Yin

Since Specialization

Citations

This map shows the geographic impact of Donghua Yin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Donghua Yin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Donghua Yin more than expected).

Fields of papers citing papers by Donghua Yin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Donghua Yin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Donghua Yin. The network helps show where Donghua Yin may publish in the future.

Co-authorship network of co-authors of Donghua Yin

This figure shows the co-authorship network connecting the top 25 collaborators of Donghua Yin. A scholar is included among the top collaborators of Donghua Yin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Donghua Yin. Donghua Yin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yin, Donghua, et al.. (2025). Landscape analysis of adverse events and dose intensity for FDA approved oncology small molecules. Cancer Chemotherapy and Pharmacology. 95(1). 17–17.

Shang, Charles, et al.. (2025). Radiofrequency for Chronic Knee Pain: A Literature Review. Journal of Pain Research. Volume 18. 2203–2213. 1 indexed citations

Williams, Jason H., et al.. (2024). Implications of Immunogenicity Testing for Therapeutic Monoclonal Antibodies: A Quantitative Pharmacology Framework. The AAPS Journal. 26(2). 31–31.

Ruiz-Garcı́a, Ana, Paul Baverel, Dean Bottino, et al.. (2023). A comprehensive regulatory and industry review of modeling and simulation practices in oncology clinical drug development. Journal of Pharmacokinetics and Pharmacodynamics. 50(3). 147–172. 28 indexed citations

Liao, Ken, et al.. (2022). Joint Disposition Properties and Comprehensive Pharmacokinetic Characterization of Antibody–Drug Conjugates. The AAPS Journal. 24(4). 73–73. 2 indexed citations

Noel, Marcus Smith, Eileen M. O’Reilly, Brian M. Wolpin, et al.. (2019). Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma. Investigational New Drugs. 38(3). 800–811. 145 indexed citations

Pegram, Mark D., Igor Bondarenko, Hirotaka Iwase, et al.. (2018). PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: a randomised, double-blind study. British Journal of Cancer. 120(2). 172–182. 50 indexed citations

Freyman, Amy, Steven D. Reich, Donghua Yin, et al.. (2016). Evaluating imbalances of adverse events during biosimilar development. mAbs. 8(5). 861–866. 2 indexed citations

Cohen, Stanley, Paul Emery, Maria Greenwald, et al.. (2016). A phase I pharmacokinetics trial comparing PF‐05280586 (a potential biosimilar) and rituximab in patients with active rheumatoid arthritis. British Journal of Clinical Pharmacology. 82(1). 129–138. 46 indexed citations

10.

Yin, Donghua, Chandrasekhar Udata, Steven Y. Hua, et al.. (2015). Mo1221 Comparative Assessments of PF-06438179, a Potential Biosimilar, and Infliximab in a Phase 1 Pharmacokinetic Study. Gastroenterology. 148(4). S–642. 3 indexed citations

11.

Yin, Donghua, Kerry Barker, Ruifeng Li, et al.. (2014). A randomized phase 1 pharmacokinetic trial comparing the potential biosimilarPF‐05280014 with trastuzumab in healthy volunteers (REFLECTIONS B327‐01). British Journal of Clinical Pharmacology. 78(6). 1281–1290. 60 indexed citations

12.

Becerra, Carlos, Ramón Salazar, Rocio García‐Carbonero, et al.. (2014). Figitumumab in patients with refractory metastatic colorectal cancer previously treated with standard therapies: a nonrandomized, open-label, phase II trial. Cancer Chemotherapy and Pharmacology. 73(4). 695–702. 23 indexed citations

13.

Juergens, Heribert, Najat C. Daw, Birgit Geoerger, et al.. (2011). Preliminary Efficacy of the Anti-Insulin–Like Growth Factor Type 1 Receptor Antibody Figitumumab in Patients With Refractory Ewing Sarcoma. Journal of Clinical Oncology. 29(34). 4534–4540. 165 indexed citations

14.

Olmos, David, Sophie Postel‐Vinay, L Rhoda Molife, et al.. (2009). Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study. The Lancet Oncology. 11(2). 129–135. 269 indexed citations

15.

Karp, Daniel D., Michaël Pollak, Roger B. Cohen, et al.. (2009). Safety, Pharmacokinetics, and Pharmacodynamics of the Insulin-Like Growth Factor Type 1 Receptor Inhibitor Figitumumab (CP-751,871) in Combination with Paclitaxel and Carboplatin. Journal of Thoracic Oncology. 4(11). 1397–1403. 48 indexed citations

16.

Lacy, Martha Q., Melissa Alsina, Rafaël Fonseca, et al.. (2008). Phase I, Pharmacokinetic and Pharmacodynamic Study of the Anti–Insulinlike Growth Factor Type 1 Receptor Monoclonal Antibody CP-751,871 in Patients With Multiple Myeloma. Journal of Clinical Oncology. 26(19). 3196–3203. 122 indexed citations

17.

Lacy, Martha Q., Melissa Alsina, Rafaël Fonseca, et al.. (2007). Phase 1 Dose Escalation Study of the Monoclonal Antibody Against the Insulin Like Growth Factor I Receptor CP-751,871 in Patients with Multiple Myeloma.. Blood. 110(11). 1171–1171. 3 indexed citations

18.

Yin, Donghua, Franzanne Vreeland, Larry J. Schaaf, et al.. (2007). Clinical Pharmacodynamic Effects of the Growth Hormone Receptor Antagonist Pegvisomant: Implications for Cancer Therapy. Clinical Cancer Research. 13(3). 1000–1009. 56 indexed citations

19.

Perera, Minoli A., Donghua Yin, Di Wu, et al.. (2006). In Vivo Metabolism and Final Disposition of a Novel Nonsteroidal Androgen in Rats and Dogs. Drug Metabolism and Disposition. 34(10). 1713–1721. 18 indexed citations

20.

Yin, Donghua, Huiping Xu, Yali He, et al.. (2003). Pharmacology, Pharmacokinetics, and Metabolism of Acetothiolutamide, a Novel Nonsteroidal Agonist for the Androgen Receptor. Journal of Pharmacology and Experimental Therapeutics. 304(3). 1323–1333. 37 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact